Literature DB >> 32928734

In Vivo Pharmacodynamic Target Assessment of Antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Neutropenic Murine Pneumonia Model.

Yu-Feng Zhou1,2, Ping Liu1,2, Shu-He Dai1,2, Jian Sun1,2, Ya-Hong Liu1,2,3, Xiao-Ping Liao4,2.   

Abstract

We determined in vivo efficacy and target PK/PD exposures of antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in the murine pneumonia model. The mean plasma free drug area under the concentration-time curve/MIC (fAUC/MIC) targets associated with stasis and 1-log10 and 2-log10 kill effects were 8.93, 19.2, and 48.1, respectively, for S. pneumoniae, whereas they were 30.5, 55.4, and 115.8, respectively, for S. aureus The fAUC/MIC targets in murine lung epithelial lining fluids (ELF) for the same endpoints were nearly 2-fold higher than those in plasma.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  MRSA; PK/PD; Streptococcus pneumoniae; antofloxacin; pneumonia

Mesh：

Substances：

Year:  2020        PMID： 32928734      PMCID： PMC7674040          DOI： 10.1128/AAC.01354-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model.

Authors:  Yu-Feng Zhou; Meng-Ting Tao; Wei Huo; Xiao-Ping Liao; Jian Sun; Ya-Hong Liu
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.

Authors:  Abrar K Thabit; Jared L Crandon; David P Nicolau
Journal:  Int J Antimicrob Agents       Date:  2016-09-29       Impact factor: 5.283

4.  Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Authors:  P G Ambrose; D M Grasela; T H Grasela; J Passarell; H B Mayer; P F Pierce
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers.

Authors:  Yuan Lü; Zi-Sheng Kang; Yan Zhu; Ming Zhang; Yan Liu; Man Zhang; Tian-Yun Li; Yong-Hong Xiao
Journal:  Chin Med J (Engl)       Date:  2011-01       Impact factor: 2.628

6.  A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections.

Authors:  Jin Wang; Yonghong Xiao; Wenxiang Huang; Nan Xu; Chunxue Bai; Qingyu Xiu; Changlin Mei; Qingshan Zheng
Journal:  Chemotherapy       Date:  2010-10-12       Impact factor: 2.544

7.  Omadacycline for Community-Acquired Bacterial Pneumonia.

Authors:  Roman Stets; Monica Popescu; Joven R Gonong; Ismail Mitha; William Nseir; Andrzej Madej; Courtney Kirsch; Anita F Das; Lynne Garrity-Ryan; Judith N Steenbergen; Amy Manley; Paul B Eckburg; Evan Tzanis; Paul C McGovern; Evan Loh
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

8.  Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.

Authors:  F Scaglione; J W Mouton; R Mattina; F Fraschini
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA.

Authors:  Yu-Feng Zhou; Yan Q Xiong; Meng-Ting Tao; Liang Li; Ming-Xiao Bu; Jian Sun; Xiao-Ping Liao; Ya-Hong Liu
Journal:  J Antimicrob Chemother       Date:  2018-07-01       Impact factor: 5.790

10.  In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.

Authors:  Alexander J Lepak; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.